PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo targets genetic weakness in tough pancreatic cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy gemcitabine can help people with a certain genetic type of advanced pancreatic cancer live longer. The study enrolls 43 adults whose cancer has spread and who have already tried one…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 23, 2026 23:35 UTC
-
New drug DA-3501 takes on tough cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called DA-3501 in people with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The main goals are to find a safe dose and see if the drug can shrink tumors. Particip…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE1 • Sponsor: Dong-A ST Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Blood marker may forecast deadly pancreatic surgery complications
Knowledge-focused Recruiting nowThis study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC